BioSculpture Technology, Inc. (“BST”) filed its Form 1-A for a Tier 2 Reg. A Offering to fund development and clinical testing of its minimally invasive EVL® device for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. Excessive visceral fat within the abdominal cavity causes metabolic syndrome and type 2 diabetes, shortening lives and decreasing their quality. We believe our patented technology and procedure, Endoscopic Visceral Lipectomy (“EVL”) to remove this noxious fat, illustrated in this 70 second medical video, will save and improve millions of lives each year, while significantly reducing healthcare costs. You can listen to the highlights of our investor presentation, place an Indication of Interest in our Offering, or contact us for an interim bridge financing opportunity for Accredited Investors.